<div id="readability-page-1"><p>Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Get Free Report) have received a consensus recommendation of &#34;Moderate Buy&#34; from the nine brokerages that are currently  covering the stock, Marketbeat Ratings reports. Two analysts have rated the stock with a hold rating and seven have issued  a buy rating on  the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $23.00.</p><p>ZVRA has been the topic of a number of recent analyst reports. BTIG Research assumed coverage on Zevra Therapeutics in a report on Monday, March 16th. They issued a &#34;buy&#34; rating and a $23.00 price objective on the stock. Guggenheim  set a $23.00 target price on Zevra Therapeutics and gave the stock a &#34;buy&#34; rating in a research note on Tuesday, March 10th. HC Wainwright  set a $26.00 target price on Zevra Therapeutics in a research report on Tuesday, December 30th. Weiss Ratings raised Zevra Therapeutics from a &#34;sell (d+)&#34; rating to a &#34;hold (c+)&#34; rating in a research note on Tuesday, March 10th. Finally, Wall Street Zen upgraded Zevra Therapeutics from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a report on Saturday, April 11th.</p><div><p><span></span><span>Get <strong>Zevra Therapeutics</strong> alerts:</span></p></div><p><b>Read Our Latest Report on Zevra Therapeutics</b></p><h2>Zevra Therapeutics Stock Performance</h2><p>NASDAQ:ZVRA opened at $10.32 on Thursday. The company's 50-day moving average is $9.23 and its two-hundred day moving average is $9.26. Zevra Therapeutics has a 1-year low of $6.77 and a 1-year high of $13.16. The company has a debt-to-equity ratio of 0.40, a current ratio of 5.68 and a quick ratio of 5.63. The firm has a market capitalization of $605.89 million, a price-to-earnings ratio of 7.76 and a beta of 0.89. </p><h2>Insider Activity at Zevra Therapeutics</h2><p>In other Zevra Therapeutics news, insider Joshua Schafer sold 10,500 shares of the stock in a transaction dated Tuesday, February 3rd. The shares were sold at an average price of $9.19, for a total transaction of $96,495.00. Following the completion of the transaction, the insider owned 62,278 shares of the company's stock, valued at $572,334.82. This trade represents a 14.43% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Timothy J. Sangiovanni sold 3,000 shares of the business's stock in a transaction that occurred on Tuesday, February 3rd. The shares were sold at an average price of $9.18, for a total transaction of $27,540.00. Following the completion of the sale, the senior vice president directly owned 29,590 shares in the company, valued at $271,636.20. This trade represents a 9.21% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 114,158 shares of company stock worth $1,062,878. 2.40% of the stock is owned by corporate insiders. </p><h2>Institutional Inflows and Outflows</h2><p>Several hedge funds and other institutional investors have recently modified their holdings of ZVRA. Gunpowder Capital Management LLC dba Oliver Wealth Management purchased a new stake in shares of  Zevra Therapeutics in the 4th quarter valued at $53,000.  DGS Capital Management LLC purchased a new position in  Zevra Therapeutics during the 4th quarter valued at about $133,000.  Millennium Management LLC boosted its holdings in  Zevra Therapeutics by 9.6% during the 4th quarter. Millennium Management LLC now owns 1,134,358 shares of the company's stock valued at $10,164,000 after acquiring an additional 99,107 shares during the period.  Man Group plc grew its position in  Zevra Therapeutics by 174.4% in the 4th quarter. Man Group plc now owns 92,347 shares of the company's stock valued at $827,000 after acquiring an additional 58,695 shares in the last quarter.  Finally, Engineers Gate Manager LP increased its stake in  Zevra Therapeutics by 23.4% during the fourth quarter. Engineers Gate Manager LP now owns 44,020 shares of the company's stock worth $394,000 after purchasing an additional 8,359 shares during the period. 35.03% of the stock is currently owned by hedge funds and other institutional investors. </p><h2>Zevra Therapeutics Company Profile</h2> (Get Free Report)<p>Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.</p><h2>Recommended Stories</h2><ul><li>Five stocks we like better than Zevra Therapeutics</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9WlZSQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9WlZSQQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Zevra Therapeutics Right Now?</h2><p>Before you consider Zevra Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zevra Therapeutics wasn't on the list.</p><p>While Zevra Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ZVRA

IBBQ

<p>Zevra Therapeutics, Inc. (NASDAQ:ZVRA) has received a consensus recommendation of "Moderate Buy" from nine brokerages. Two analysts rated it as hold, while seven issued buy ratings. The average 12-month price target is $23.00. Recent analyst reports include BTIG Research and Guggenheim, both setting a $23.00 target. The stock opened at $10.32, with a market cap of $605.89 million. Insider trading shows a decrease in ownership by key insiders. Institutional investors hold 35.03% of the stock, with recent purchases from various hedge funds.</p>

Market Beat

Zevra Therapeutics

Invesco Nasdaq Biotechnology ETF

iShares US Pharma

First Trust NYSE Arca Biotech Index Fd

Health Care Select Sector SPDR

VanEck Biotech ETF

Ark Genomic Revolution ETF

ALPS Medical Breakthrough

VG Health

Proshares Ultra Nasdaq Biotech

Invesco Biotechnology & Genome ETF

iShares Global Healthcare

Direxion S&P Biotech Bull 3X

iShares Biotechnology ETF

SPDR S&P Biotech

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives Average Recommendation of "Moderate Buy" from Analysts